![](https://news.europawire.eu/wp-content/uploads/2022/01/Almirall-144x144.jpg)
Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release